Fill out this medical information card with the contact information of your/your child's doctor. Keep it with you, or have your child keep it on them, while on BLINCYTO® treatment.

Fo	iu
About me:	Learn more at www.BLINCYTO.com
Name	SECOLOGIA MARINE SECTION OF
Phone	руоие
My parent or caregiver:	уате
Name	
Phone	About my doctor:
AMCFIN® is a registered trademark of Amgen Inc. © 2022 Amgen Inc. All rights reserved. USA-103-81059 01/22	Seizures Descripty in speaking or Doss of balance Surried speech Loss of consciousness Doss of consciousness Trouble sleeping
Fill out this medical information card. You can keep your important health care contact information in one place here. There is also information on some possible side effects.	• Tiredness or weakness • Dizziness • Dizziness • Dizziness • Low blood pressure • Low blood pressure • Low blood pressure • Low blood pressure • Skin rash • Mausea **Aurologic problems Symptoms may include:
Medical information card Patient is receiving BLINCYTO® for the treatment:	Cytokine release syndrome and infusion reactions Symptoms may include: • Fever
NDICATIONS BLINCYTO® (blinatumomab) is a prescription medicine used to treat	BLINCYTO® may cause serious side effects that can be severe, life-threatening, or fatal, including:
B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit. BLINCYTO® is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a cancer of the blood and bone marrow in which a particular kind of white blood cell is replicating out of control.	IMPORTANT NOTE FOR HEALTH CARE PROFESSIONALS: Do not flush the BLINCYTO® infusion line or intravenous catheter, bags or at completion of infusion can result in excess dosage and cause complications. When administering via a multi-lumen venous catheter, infuse BLINCYTO® through a dedicated lumen. Please contact your prescribing provider with any questions

Please contact your prescribing provider with any questions.

Please <u>click here</u> for Prescribing Information and the Medication Guide.

Please contact your prescribing provider with any questions. Please click here for Prescribing Information and the Medication Guide.

Do not flush the especially when of bags or at completed and cause completed venous catheter, Please contact y	EFOR HEALTH CARE PROFESSIONALS: SLINCYTO® infusion line or intravenous catheter, hanging infusion bags. Flushing when changing stion of infusion can result in excess dosage cations. When administering via a multi-lumen infuse BLINCYTO® through a dedicated lumen. ur prescribing provider with any questions ause serious side effects that can be severe, or fatal, including:	INDICATIONS BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are anyoging studies to confirm clinical benefit. BLINCYTO® is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a centes of the blood and bone marrow in a centes of the blood and bone marrow in cell is replicating out of control.
Symptoms may in Fever Tiredness or wece Dizziness	Vomiting Chills Face swelling	Medical information card Patient is receiving BLINCYTO® for the treatment:
HeadacheLow blood pressNausea Neurologic probl		Fill out this medical information card. You can keep your important health care contact information in one place here.
Symptoms may in		There is also information on some possible side effects.
SeizuresDifficulty in spec slurred speech	Headache	AMGEN°
Loss of consciouTrouble sleeping	 Difficulty with facial movements, hearing, vision, or swallowing 	BLINCYTO® is a registered trademark of Amgen Inc. © 2022 Amgen Inc. All rights reserved. USA-103-81059 01/22
About my doct	or:	- Phone
		Лате
Name		My parent or caregiver:
Phone		- Биоие
	BUNGVEG	Лате
Learn more at www.BLINCYTO.com		About me:

Fill out this medical information card with the contact information of your/your child's doctor. Keep it with you, or have your child keep it on them, while on $BLINCYTO^{\otimes}$ treatment.